Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
1994677 citationsThierry Le Chevalier, D. Brisgand et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of P Chomy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Chomy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Chomy more than expected).
This network shows the impact of papers produced by P Chomy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Chomy. The network helps show where P Chomy may publish in the future.
Co-authorship network of co-authors of P Chomy
This figure shows the co-authorship network connecting the top 25 collaborators of P Chomy.
A scholar is included among the top collaborators of P Chomy based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with P Chomy. P Chomy is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Gatzemeier, U., C. Manegold, Hans‐Joachim Wilke, et al.. (1998). Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer.. PubMed. 25(1 Suppl 2). 15–8.10 indexed citations
Chevalier, Thierry Le, D. Brisgand, Jean Louis Pujol, et al.. (1996). [Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer].. PubMed. 83(5). 385–94.7 indexed citations
Chevalier, Thierry Le, D. Brisgand, Jean‐Yves Douillard, et al.. (1994). Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.. Journal of Clinical Oncology. 12(2). 360–367.677 indexed citations breakdown →
Beylot, J, et al.. (1989). [Diagnosis of bilateral secondary tumors of the kidney. Contribution of cytology. Apropos of 2 cases].. PubMed. 140(5). 368–71.1 indexed citations
16.
Ballanger, P, et al.. (1986). [Spontaneous regression of pulmonary images interpreted as metastases of kidney cancer. Apropos of 2 cases].. PubMed. 20(4). 271–4.3 indexed citations
17.
Chomy, P, et al.. (1970). [Provocation tests with allergen inhalation: technics, results and importance for the allergologic appraisal of the asthmatic patient].. PubMed. 3(7). 1817–26.1 indexed citations
18.
Fréour, P, et al.. (1967). [Initial results of the treatment of pulmonary tuberculosis with ethambutol in adults].. PubMed. 31(7). 1066–78.
19.
Fréour, P, et al.. (1966). [On a case of spontaneous chylothorax in an adult. (Lymphographic and angiographic study)].. PubMed. 20(3). 281–91.1 indexed citations
20.
Fréour, P, et al.. (1966). ["Beauveria" fungi in human pathology. Apropos of a case of pulmonary localization].. PubMed. 74(45). 2317–20.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.